Skip to Content
  • More Movements at the Top of GSK

    GlaxoSmithKline has been having more than its share of ups and downs over the last few years. In 2014, they moved a lot of assets out of oncology, as part of a… Read More
  • The Drug Project Landscape

    Here’s a new paper in Nature Reviews Drug Discovery that’s going to the trouble of matching specific disease indications with specific mechanisms in… Read More
  • Whole Classes of Things

    We all know about target-based drug discovery. Enough biology has been learned that we think that Protein X is operating at a crucial stage in the development o… Read More
  • Alnylam Breaks Through

    As a pioneer in RNAi therapeutics, Alnylam has really had some ups and downs over the years (some of them chronicled on this blog). Today would be one of the &# Read More
  • Where MRSA Came From

    OK, everyone recognizes the problem that we face with drug-resistant bacteria. MRSA (methicillin-resistant Staphylococcus aureus) is the most well-known variety… Read More
  • How Long, Oh Lord, How Long?

    Here we have the prototypical slow summer day. So I’m going to use this one to throw a question out to the readership: those of you in preclinical drug di… Read More
  • GSK Rearranges, Once More

    There have been a lot of announcements in the biopharma field this week, and I’m just now getting around to GlaxoSmithKline’s from a couple of days… Read More
  • The Keytruda Story

    This is a good history of Keytruda, the Merck immuno-oncology blockbuster, from David Shaywitz. Most big drugs have a tangled history, and this one is certainly… Read More
  • Following Up

    Here’s a question that I’m not sure if there’s a general answer to: if you’re putting together a drug discovery portfolio, what percenta… Read More
Page 1 of 3912345...102030...Last »